Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

Anthonie J. van der Wekken; Klaas Kok; Harry J. M. Groen

doi:10.21037/jtd.2018.06.45

Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

Anthonie J. van der Wekken^*
, Klaas Kok
, Harry J. M. Groen

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	S2130-S2132
Number of pages	3
Journal	Journal of thoracic disease
Volume	10
Issue number	Supp 18
DOIs	https://doi.org/10.21037/jtd.2018.06.45
Publication status	Published - Jul-2018

Keywords

CRIZOTINIB
RESISTANCE
INHIBITOR

Access to Document

10.21037/jtd.2018.06.45

Handle.net

Persistent link

Embargoed Document

Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
Final publisher's version, 127 KB

Cite this

@article{5e65d80334054c509766ccd856a1d6ee,

title = "Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?",

keywords = "CRIZOTINIB, RESISTANCE, INHIBITOR",

author = "\{van der Wekken\}, \{Anthonie J.\} and Klaas Kok and Groen, \{Harry J. M.\}",

year = "2018",

month = jul,

doi = "10.21037/jtd.2018.06.45",

language = "English",

volume = "10",

pages = "S2130--S2132",

journal = "Journal of thoracic disease",

issn = "2072-1439",